Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 12Active not recruiting 4Not yet recruiting 3Suspended 2Withdrawn 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Thoracic 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Specimen Handling 191Magnetic Resonance Spectroscopy 141Biopsy 102pembrolizumab 82Carboplatin 76Cisplatin 68Nivolumab 62Radiotherapy 51Paclitaxel 51Gemcitabine 50Cyclophosphamide 48Dexamethasone 46durvalumab 39Radiation 39atezolizumab 36Pemetrexed 36olaparib 34Rituximab 34venetoclax 33Etoposide 33Doxorubicin 32Lenalidomide 31X-Rays 30Prednisone 30Bevacizumab 30Docetaxel 28Disulfides 28Immunoglobulin G 27Vincristine 26Ipilimumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
102 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04975919 2026-05-14

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT02998567 2026-05-12

HyPeR

Royal Marsden NHS Foundation Trust

Phase 1 Active not recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡